Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations

被引：0
|
作者：
Wu, L. [1 ]
Pu, X. [2 ]
Zhou, Y. [2 ]
Kong, Y. [2 ]
Chen, B. [2 ]
Yang, A. [3 ]
Li, J. [2 ]
Li, K. [2 ]
Xu, Y. [2 ]
机构：
[1] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[2] Hunan Canc Hosp, Dept Thorac Oncol 2, Changsha, Peoples R China
[3] Hunan Canc Hosp, Dept Radiotherapy, Changsha, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574P
引用
收藏
页码：S1695 / S1695
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
    Liao, Chen
    Bai, Li
    He, Tingting
    Liang, Qingle
    Hu, Defeng
    Lei, Shipeng
    He, Yong
    Wang, Yubo
    CANCER MEDICINE, 2025, 14 (01):
  • [42] KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naive, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Garassino, M. C.
    Theelen, W. S. M. E.
    Jotte, R.
    Laskin, J.
    De Marinis, F.
    Aguado, C.
    Badin, F. B.
    Chmielewska, I.
    Hochmair, M. J.
    Lu, S.
    Nadal, E.
    Ostoros, G.
    Felip, E.
    Spira, A. I.
    Lane, C. M.
    He, J.
    Chao, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1309 - S1310
  • [43] A PHASE II STUDY OF ERLOTINIB AS FIRST-LINE TREATMENT IN JAPANESE ADVANCED NSCLC PATIENTS HARBORING EGFR MUTATIONS
    Horiike, A.
    Nishio, M.
    Goto, K.
    Yamamoto, N.
    Chikamori, K.
    Maemondo, M.
    Hida, T.
    Katakami, N.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 413 - 413
  • [44] Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
    Jiang, Yingying
    Fang, Xiaoxu
    Xiang, Yan
    Fang, Tingwen
    Liu, Jingwen
    Lu, Kaihua
    CURRENT ONCOLOGY, 2023, 30 (06) : 5337 - 5349
  • [45] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Lee, Yoo Jung
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [46] Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma
    Weber, J. S.
    Berman, D.
    Siegel, J.
    Minor, D.
    Amin, A.
    Thompson, J. A.
    Ron, I.
    Ridolfi, R.
    Assi, H.
    Hamid, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
    Mok, T.
    Nakagawa, K.
    Rosell, R.
    Lee, K.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Devgan, G.
    Sbar, E.
    Quinn, S.
    Wang, T.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S454 - S454
  • [48] Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2024, 72 (02): : 107 - 113
  • [49] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Kang, Hye Seon
    Kim, Kyu Yeon
    Lim, Jeong Uk
    Yeo, Chang Dong
    Kim, Ju Sang
    Kim, Seung Joon
    Lee, Sang Haak
    RESPIROLOGY, 2023, 28 : 100 - 100
  • [50] Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations
    Wang, Y.
    Wang, Y.
    Tian, P.
    Han, R.
    Li, L.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
12345